about
Galactose-modified iNKT cell agonists stabilized by an induced fit of CD1d prevent tumour metastasis.Enhanced TCR Footprint by a Novel Glycolipid Increases NKT-Dependent Tumor ProtectionAn in silico approach for modelling T-helper polarizing iNKT cell agonistsPhase I dose-escalation study of plitidepsin in combination with sorafenib or gemcitabine in patients with refractory solid tumors or lymphomas.Phase I dose-escalation study of milciclib in combination with gemcitabine in patients with refractory solid tumors.Activated iNKT cells promote memory CD8+ T cell differentiation during viral infectionPreclinical evaluation of invariant natural killer T cells in the 5T33 multiple myeloma modelCancer immunotherapy: from the lab to clinical applications-Potential impact on cancer centres' organisation.NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients.Invariant natural killer T cells in rheumatic disease: a joint dilemma.Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score).Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies.Rationale for anti-OX40 cancer immunotherapy.TILs in Head and Neck Cancer: Ready for Clinical Implementation and Why (Not)?Turning the tide: Clinical utility of PD-L1 expression in squamous cell carcinoma of the head and neck.Divergent synthetic approach to 6''-modified α-GalCer analogues.Pharmacological sensitivity of ATP release triggered by photoliberation of inositol-1,4,5-trisphosphate and zero extracellular calcium in brain endothelial cells.Synthesis of C-5″ and C-6″-modified α-GalCer analogues as iNKT-cell agonists.RECIST response and variation of circulating tumour cells in phase 1 trials: A prospective multicentric study.Bacterial CD1d-restricted glycolipids induce IL-10 production by human regulatory T cells upon cross-talk with invariant NKT cells.Synthesis and evaluation of amino-modified alpha-GalCer analogues.Tumor PD-L1 status and CD8+ tumor-infiltrating T cells: markers of improved prognosis in oropharyngeal cancer.In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies?Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease.Challenges and perspectives in the immunotherapy of Hodgkin lymphoma.Onset of connective tissue disease following anti-PD1/PD-L1 cancer immunotherapy.Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors).Are phase I trials safe for older patients?Prognostic markers in oropharyngeal squamous cell carcinoma: focus on CD70 and tumour infiltrating lymphocytes.Synthesis of 6"-triazole-substituted α-GalCer analogues as potent iNKT cell stimulating ligands.Epigenetic modifiers as new immunomodulatory therapies in solid tumours.Immuno-oncology-101: overview of major concepts and translational perspectives.Phase I dose-escalation study of plitidepsin in combination with bevacizumab in patients with refractory solid tumors.Rapid and objective CT scan prognostic scoring identifies metastatic patients with long-term clinical benefit on anti-PD-1/-L1 therapy.CD70 Expression and Its Correlation with Clinicopathological Variables in Squamous Cell Carcinoma of the Head and Neck.Immunotherapy phase I trials in patients Older than 70 years with advanced solid tumours.3D waterfall plots: a better graphical representation of tumor response in oncology.Acquired EGFR Mutation as the Potential Resistance Driver to Crizotinib in a MET-Mutated Tumor.
P50
Q27667759-63537AF4-4B1C-4B6E-8679-B56D65C00D75Q27679771-69C45E29-68BE-49BB-A044-1472A18582D4Q28539366-7C12B422-CD08-4F9C-82FC-285545E639D5Q33437640-351BA4AC-D739-4AE8-A30C-214C0D85678AQ33441161-172DE4FA-97B2-43F1-845D-6C4EC314C341Q34287659-73F46A5C-98E1-4331-865E-4814C7063329Q34761156-8E564297-0BBD-4D82-940E-6FC19EAA45A6Q37458758-A387E13A-BD1C-4F06-9B0A-4B5C4D83C6E7Q37616478-64493EFF-5F23-42AE-9C1B-0DDFE1C5E955Q37686081-5ABA9AE4-4CAB-411D-AE24-F58B80EC3822Q38616101-92840D26-EDF1-43AE-AC92-3FFB09B29323Q38636711-6D146E6A-EE7B-4C85-876E-8CE43CD6F48EQ38662311-787ACB59-0C69-429A-A669-AB95865E97EBQ39055075-2CDB7D73-41C7-47D8-8B1E-5180286E8F4DQ39378983-3F6A2769-E751-4D80-A18A-E217C6006DDCQ40000485-37D600C3-6C4B-4C7D-9BF9-2060C210BCB3Q40632649-DE6D8E7F-DBEB-49FB-A40F-372DFAF0161DQ40908607-E8DE97DC-3770-4E60-82A9-BC1C6ACBA7D7Q42698052-3C63E0F5-B46D-42E0-8C36-CAB9045FADEBQ42710075-AA6F5B14-E246-44EA-A173-57168E16B817Q42733983-463D8297-12FB-4744-ACB0-EDCADB8CCDB7Q43291647-87BB1FA8-82D4-4FC3-B9AF-4A493778E2BBQ47416333-0A8BF4D5-8C68-4A9A-A573-EC03DB35E97BQ47553922-A1B41086-9D2D-4E46-BB9F-217664B7A3A8Q47822429-278F6954-1280-47D2-9EDE-AA04A95A0533Q47873563-F3EF2D35-0191-4C0B-858C-0D9EFD3DA35FQ47927037-9F1E12FE-836A-4DDA-9C5E-DDFEF51CDD95Q48006518-E0E43EF2-D9F7-4C78-983E-787EDCA3B49BQ49101841-90A774E7-6C0D-46EA-90DB-12AC121BEF69Q49149027-CD947C4F-FF67-4C5E-8E96-018631348EFEQ50061829-72E05231-B5B3-4902-81BD-F3A312788287Q50082795-3D04E7B8-C031-49B0-AAA7-C7B92C67217CQ51526168-9B6AE9E4-2409-433E-9D21-B0D5739BD7E5Q51621001-EA3CC5CA-B20B-4678-B9BB-FC31B513307DQ51656472-5270ED23-AE6D-489E-9558-3408E1D4778CQ52596199-09E59F50-EBE9-4D03-A5AC-F1BE173318E7Q53715998-A5BBC471-99BE-43E7-9FE8-90C628113453Q53798805-7CD49A07-A252-492B-9047-CD399EA643E1
P50
description
Belgisch oncologe
@nl
oncóloga belxicana
@ast
researcher ORCID ID = 0000-0001-6598-9161
@en
name
Sandrine Aspeslagh
@ast
Sandrine Aspeslagh
@ca
Sandrine Aspeslagh
@de
Sandrine Aspeslagh
@en
Sandrine Aspeslagh
@es
Sandrine Aspeslagh
@fr
Sandrine Aspeslagh
@ga
Sandrine Aspeslagh
@it
Sandrine Aspeslagh
@nl
Sandrine Aspeslagh
@sl
type
label
Sandrine Aspeslagh
@ast
Sandrine Aspeslagh
@ca
Sandrine Aspeslagh
@de
Sandrine Aspeslagh
@en
Sandrine Aspeslagh
@es
Sandrine Aspeslagh
@fr
Sandrine Aspeslagh
@ga
Sandrine Aspeslagh
@it
Sandrine Aspeslagh
@nl
Sandrine Aspeslagh
@sl
prefLabel
Sandrine Aspeslagh
@ast
Sandrine Aspeslagh
@ca
Sandrine Aspeslagh
@de
Sandrine Aspeslagh
@en
Sandrine Aspeslagh
@es
Sandrine Aspeslagh
@fr
Sandrine Aspeslagh
@ga
Sandrine Aspeslagh
@it
Sandrine Aspeslagh
@nl
Sandrine Aspeslagh
@sl
P106
P1960
Hxrd5k8AAAAJ
P2002
sandrineaspesla
P21
P27
P31
P3835
sandrine-aspeslagh
P496
0000-0001-6598-9161
P6634
sandrineaspeslagh